References

  1. Micardis PI. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2009.
  2. Twynsta PI. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2009.
  3. Micardis HCT PI. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2009.
  4. Yusuf S, Teo K, Anderson C, et al; and the TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174-1183.
  5. Yusuf S, Teo K, Pogue J, et al; and the ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
  6. Yusuf S, Sleight P, Pogue J, et al; and the HOPE Study Investigators. Effects of an angiotensin-converting�enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
  7. Altace PI. Bristol, TN: King Pharmaceuticals, Inc.; 2008.
  8. McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ. 2006; 332(7551):1177-1181.
  9. Woo KS, Norris RM, Nicholls G. Racial difference in incidence of cough with angiotensin-converting enzyme inhibitors (a tale of two cities). Am J Cardiol. 1995;75(14):967-968.
  10. Lip GYH, Beevers DG. Doctors, nurses, pharmacists and patients�the rational evaluation and choice in hypertension (REACH) survey of hypertension care delivery. Blood Press. 1997;6(Suppl 1):6-10.
  11. Wallenius SH, Vainio KK, Korhonen MJH, et al. Self-initiated modification of hypertension treatment in response to perceived problems. Ann Pharmacother. 1995;29:1213-1217.
  12. Data on file. Study 502.373 (Doc. No.: U08-1821-01; ONTARGET).
  13. Teo K, Yusuf S, Sleight P, et al; and the ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J. 2004;148:52-61.
  14. Benicar PI. Parsippany, NJ: Daiichi Sankyo, Inc.; 2007.
  15. Diovan PI. East Hanover, NJ: Novartis Pharmaceuticals Corp.; 2008.